This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
by Zacks Equity Research
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
BIIBPositive Net Change ANIPNegative Net Change LRMRNegative Net Change ALXOPositive Net Change
biotechs medical pharmaceuticals
QURE Stock Crashes 32% in a Week: Here's What You Should Know
by Zacks Equity Research
uniQure stock plunges 32% in a week after the FDA says AMT-130 phase I/II Huntington's disease data are not sufficient as primary evidence for a potential marketing application.
USNAPositive Net Change QURENegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
by Zacks Equity Research
Tango Therapeutics stock hits a record high after signing a clinical collaboration with Erasca to test the ERAS-0015/vopimetostat combo in MTAP-deleted RAS-mutant cancers.
USNAPositive Net Change ERASNegative Net Change TNGXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Best Health & Fitness Stocks to Buy Now for Strong Growth
by Nilanjan Choudhury
GRMN, HLF and AMWL stand out in a booming wellness market as wearables, nutrition products and telehealth platforms reshape how consumers pursue healthier lives.
AMZNNegative Net Change AAPLPositive Net Change GRMNPositive Net Change HLFPositive Net Change AMWLPositive Net Change
biotechnology biotechs healthcare medical-devices thematic
Mirum Completes Enrollment & Screening in Liver Disease Studies
by Zacks Equity Research
MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.
ANIPNegative Net Change REPLNegative Net Change MIRMNegative Net Change ALXOPositive Net Change
biotechs
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
by Sundeep Ganoria
ABBV's neuroscience unit delivered $10.8B in 2025 and can hit $12.5B in 2026 as Vyalev gains traction and new Parkinson's drug tavapadon awaits FDA review.
BIIBPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
by Zacks Equity Research
Reblozyl tops $2.3B in annualized sales, emerging as a key drug for Bristol Myers as demand rises in MDS-related anemia and new study data support expansion.
BMYPositive Net Change GERNNegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Advances Roundup Settlement With Missouri Court Approval
by Zacks Equity Research
BAYRY wins preliminary court approval for a proposed Roundup class settlement, a key step in managing long-running glyphosate litigation and future liabilities.
BAYRYNo Net Change ANIPNegative Net Change REPLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
by Zacks Equity Research
IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.
ANIPNegative Net Change IMVTPositive Net Change
biotechs
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
by Debanjana Dey
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead? Let's see.
GHNegative Net Change BIAFNegative Net Change
biotechnology biotechs genetics medical medical-devices